'Boob ops put before life drug' FUNDING.
Sufferers across the country are unable to get new wonder treatment Sutent.
Despite research that it can extend life by two years or more, primary care trusts say it is not proven and too expensive at pounds 3,000 a month.
Islington in North London is one of many PCTs that put breast reduction patients before such cancer cases.
It is "following guidance" rom drug body Nice which will not rule on Sutent and another drug Nexavar until next year.
But Prof Jonathan Waxman, of London's Hammersmith Hospital, said: "It seems hard to believe that cosmetic ops get priority over cancer."